Cargando…

Theranostic Advances of Bionanomaterials against Gestational Diabetes Mellitus: A Preliminary Review

Gestational diabetes mellitus (GDM) is the most frequent complication during pregnancy. This complex disease is characterized by glucose intolerance and consequent hyperglycemia that begins or is first diagnosed in pregnancy, and affects almost 7% of pregnant women. Previous reports have shown that...

Descripción completa

Detalles Bibliográficos
Autores principales: Barani, Mahmood, Sargazi, Saman, Mohammadzadeh, Vahideh, Rahdar, Abbas, Pandey, Sadanand, Jha, Niraj Kumar, Gupta, Piyush Kumar, Thakur, Vijay Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544389/
https://www.ncbi.nlm.nih.gov/pubmed/34698244
http://dx.doi.org/10.3390/jfb12040054
_version_ 1784589806988165120
author Barani, Mahmood
Sargazi, Saman
Mohammadzadeh, Vahideh
Rahdar, Abbas
Pandey, Sadanand
Jha, Niraj Kumar
Gupta, Piyush Kumar
Thakur, Vijay Kumar
author_facet Barani, Mahmood
Sargazi, Saman
Mohammadzadeh, Vahideh
Rahdar, Abbas
Pandey, Sadanand
Jha, Niraj Kumar
Gupta, Piyush Kumar
Thakur, Vijay Kumar
author_sort Barani, Mahmood
collection PubMed
description Gestational diabetes mellitus (GDM) is the most frequent complication during pregnancy. This complex disease is characterized by glucose intolerance and consequent hyperglycemia that begins or is first diagnosed in pregnancy, and affects almost 7% of pregnant women. Previous reports have shown that GDM is associated with increased pregnancy complications and might cause abnormal fetal development. At present, treatments are not suitable for the prevention and management of these patients. As an alternative therapeutic opportunity and a leading scientific technique, nanotechnology has helped enlighten the health of these affected women. Theranostic nanomaterials with unique properties and small sizes (at least <100 nm in one of their dimensions) have been recently engineered for clinics and pharmaceutics. Reducing materials to the nanoscale has successfully changed their properties and enabled them to uniquely interact with cell biomolecules. Several biosensing methods have been developed to monitor glucose levels in GDM patients. Moreover, cerium oxide nanoparticles (NPs), selenium NPs, polymeric NPs, and drug-loaded NPs loaded with therapeutic agents have been used for GDM treatment. Still, there are some challenges associated with the detection limits and toxicity of such nanomaterials. This preliminary review covers the aspects from a fast-developing field to generating nanomaterials and their applications in GDM diagnosis and treatment.
format Online
Article
Text
id pubmed-8544389
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85443892021-10-26 Theranostic Advances of Bionanomaterials against Gestational Diabetes Mellitus: A Preliminary Review Barani, Mahmood Sargazi, Saman Mohammadzadeh, Vahideh Rahdar, Abbas Pandey, Sadanand Jha, Niraj Kumar Gupta, Piyush Kumar Thakur, Vijay Kumar J Funct Biomater Review Gestational diabetes mellitus (GDM) is the most frequent complication during pregnancy. This complex disease is characterized by glucose intolerance and consequent hyperglycemia that begins or is first diagnosed in pregnancy, and affects almost 7% of pregnant women. Previous reports have shown that GDM is associated with increased pregnancy complications and might cause abnormal fetal development. At present, treatments are not suitable for the prevention and management of these patients. As an alternative therapeutic opportunity and a leading scientific technique, nanotechnology has helped enlighten the health of these affected women. Theranostic nanomaterials with unique properties and small sizes (at least <100 nm in one of their dimensions) have been recently engineered for clinics and pharmaceutics. Reducing materials to the nanoscale has successfully changed their properties and enabled them to uniquely interact with cell biomolecules. Several biosensing methods have been developed to monitor glucose levels in GDM patients. Moreover, cerium oxide nanoparticles (NPs), selenium NPs, polymeric NPs, and drug-loaded NPs loaded with therapeutic agents have been used for GDM treatment. Still, there are some challenges associated with the detection limits and toxicity of such nanomaterials. This preliminary review covers the aspects from a fast-developing field to generating nanomaterials and their applications in GDM diagnosis and treatment. MDPI 2021-09-28 /pmc/articles/PMC8544389/ /pubmed/34698244 http://dx.doi.org/10.3390/jfb12040054 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Barani, Mahmood
Sargazi, Saman
Mohammadzadeh, Vahideh
Rahdar, Abbas
Pandey, Sadanand
Jha, Niraj Kumar
Gupta, Piyush Kumar
Thakur, Vijay Kumar
Theranostic Advances of Bionanomaterials against Gestational Diabetes Mellitus: A Preliminary Review
title Theranostic Advances of Bionanomaterials against Gestational Diabetes Mellitus: A Preliminary Review
title_full Theranostic Advances of Bionanomaterials against Gestational Diabetes Mellitus: A Preliminary Review
title_fullStr Theranostic Advances of Bionanomaterials against Gestational Diabetes Mellitus: A Preliminary Review
title_full_unstemmed Theranostic Advances of Bionanomaterials against Gestational Diabetes Mellitus: A Preliminary Review
title_short Theranostic Advances of Bionanomaterials against Gestational Diabetes Mellitus: A Preliminary Review
title_sort theranostic advances of bionanomaterials against gestational diabetes mellitus: a preliminary review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544389/
https://www.ncbi.nlm.nih.gov/pubmed/34698244
http://dx.doi.org/10.3390/jfb12040054
work_keys_str_mv AT baranimahmood theranosticadvancesofbionanomaterialsagainstgestationaldiabetesmellitusapreliminaryreview
AT sargazisaman theranosticadvancesofbionanomaterialsagainstgestationaldiabetesmellitusapreliminaryreview
AT mohammadzadehvahideh theranosticadvancesofbionanomaterialsagainstgestationaldiabetesmellitusapreliminaryreview
AT rahdarabbas theranosticadvancesofbionanomaterialsagainstgestationaldiabetesmellitusapreliminaryreview
AT pandeysadanand theranosticadvancesofbionanomaterialsagainstgestationaldiabetesmellitusapreliminaryreview
AT jhanirajkumar theranosticadvancesofbionanomaterialsagainstgestationaldiabetesmellitusapreliminaryreview
AT guptapiyushkumar theranosticadvancesofbionanomaterialsagainstgestationaldiabetesmellitusapreliminaryreview
AT thakurvijaykumar theranosticadvancesofbionanomaterialsagainstgestationaldiabetesmellitusapreliminaryreview